Four Firms Advise on the Teva-Allergan Deal: Business of Law

Israeli drugmaker Teva Pharmaceuticals Industries Ltd. agreed to buy the generic-drug business of Allergan Plc for about $40.5 billion in cash and stock and ended its hostile bid for Mylan NV.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.